[Efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases: A systematic review and meta-analysis].

Q4 Medicine

中华男科学杂志 Pub Date : 2025-04-01

Li Yang, Bo Fang, Can-Qin He, Xu-Xin Zhan, You-Ping Xiao, Xiao-Jun Qin, Qiang Lou, Xue-Jun Shang

{"title":"[Efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases: A systematic review and meta-analysis].","authors":"Li Yang, Bo Fang, Can-Qin He, Xu-Xin Zhan, You-Ping Xiao, Xiao-Jun Qin, Qiang Lou, Xue-Jun Shang","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases.Methods: Relevant studies were retrieved from PubMed, EMBASE, Cochrane, Web of Science, Sinomed , CNKI and Wanfang databases. The Cochrane risk-of-bias assessment tool was used to evaluate the quality of included studies, and relevant data were extracted. meta-analysis was performed using RevMan 5.4 and RStudio software, and forest plots were generated.Results: Six randomized controlled trials (RCTs) were included. Compared with the control group, denosumab significantly reduced the risk of skeletal-related events (HR=0.78, 95% CI: 0.62-0.93). In terms of safety, denosumab did not increase the risk of total adverse events, severe adverse events and the adverse events higher than CTC grade 3.Conclusion: Denosumab can delay the time to first skeletal-related event with good safety. However, due to the limitations of this study, further high-quality, large-sample, multicenter RCTs are needed to confirm these findings.","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 4","pages":"349-356"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华男科学杂志","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases.

Methods: Relevant studies were retrieved from PubMed, EMBASE, Cochrane, Web of Science, Sinomed , CNKI and Wanfang databases. The Cochrane risk-of-bias assessment tool was used to evaluate the quality of included studies, and relevant data were extracted. meta-analysis was performed using RevMan 5.4 and RStudio software, and forest plots were generated.

Results: Six randomized controlled trials (RCTs) were included. Compared with the control group, denosumab significantly reduced the risk of skeletal-related events (HR=0.78, 95% CI: 0.62-0.93). In terms of safety, denosumab did not increase the risk of total adverse events, severe adverse events and the adverse events higher than CTC grade 3.

Conclusion: Denosumab can delay the time to first skeletal-related event with good safety. However, due to the limitations of this study, further high-quality, large-sample, multicenter RCTs are needed to confirm these findings.

本刊更多论文

denosumab治疗前列腺癌骨转移的疗效和安全性：一项系统综述和荟萃分析。

目的：评价地诺单抗治疗前列腺癌骨转移的疗效和安全性。方法：检索PubMed、EMBASE、Cochrane、Web of Science、Sinomed、CNKI、万方等数据库的相关研究。采用Cochrane偏倚风险评估工具评价纳入研究的质量，并提取相关资料。采用RevMan 5.4和RStudio软件进行meta分析，生成森林样地。结果：纳入6项随机对照试验（RCTs）。与对照组相比，denosumab显著降低了骨骼相关事件的风险（HR=0.78, 95% CI: 0.62-0.93）。在安全性方面，denosumab没有增加总不良事件、严重不良事件和高于CTC 3级的不良事件的风险。结论：Denosumab可延迟患者发生首次骨骼相关事件的时间，且安全性较好。然而，由于本研究的局限性，需要进一步的高质量、大样本、多中心随机对照试验来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华男科学杂志 Medicine-Medicine (all)

CiteScore

0.40

自引率

0.00%

发文量

5367

期刊介绍： National journal of andrology was founded in June 1995. It is a core journal of andrology and reproductive medicine, published monthly, and is publicly distributed at home and abroad. The main columns include expert talks, monographs (basic research, clinical research, evidence-based medicine, traditional Chinese medicine), reviews, clinical experience exchanges, case reports, etc. Priority is given to various fund-funded projects, especially the 12th Five-Year National Support Plan and the National Natural Science Foundation funded projects. This journal is included in about 20 domestic databases, including the National Science and Technology Paper Statistical Source Journal (China Science and Technology Core Journal), the Source Journal of the China Science Citation Database, the Statistical Source Journal of the China Academic Journal Comprehensive Evaluation Database (CAJCED), the Full-text Collection Journal of the China Journal Full-text Database (CJFD), the Overview of the Chinese Core Journals (2017 Edition), and the Source Journal of the Top Academic Papers of China's Fine Science and Technology Journals (F5000). It has been included in the full text of the American Chemical Abstracts, the American MEDLINE, the American EBSCO, and the database.